Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Sep 20:3:218.
doi: 10.3389/fpls.2012.00218. eCollection 2012.

Challenges in O-glycan engineering of plants

Affiliations

Challenges in O-glycan engineering of plants

Richard Strasser. Front Plant Sci. .

Abstract

Plants are attractive alternative expression hosts for the production of recombinant proteins. Many therapeutic proteins are glycosylated with N- and O-glycosylation being the most prevalent forms of protein glycosylation. While N-glycans have already been modified in plants toward the formation of homogenous mammalian-type glycoforms with equal or improved biological function compared to mammalian-cell culture produced glycoproteins little attention has been paid to the modification of O-linked glycans. Recently, the first step of mammalian O-glycan biosynthesis has been accomplished in plants. However, as outlined in this short review there are important issues that have to be addressed in the future. These include: (i) elimination of potentially immunogenic or allergenic carbohydrate epitopes containing arabinosides or arabinogalactans, (ii) a detailed investigation of the interplay between engineered N- and O-glycosylation pathways to avoid competition for common metabolites like UDP-GlcNAc, and (iii) a deeper understanding of signals and mechanisms for distribution of glycan processing enzymes, which is a prerequisite for complete and homogenous glycosylation of recombinant proteins.

Keywords: glycoprotein therapeutics; glycosylation; metabolic engineering; molecular farming; secretory pathway.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
O-glycosylation engineering steps required to produce the disialylated core 1 structure which is, for example, the major O-glycan on Ser-126 of human EPO (Tsuda et al., 1990) In addition to providing CMP-NeuAc in the Golgi and initiation of O-glycosylation by transfer of a GalNAc residue the biosynthesis requires the expression of a mammalian core 1 β1,3-galactosyltransferase together with its specific chaperone Cosmc as well as α2,3- and α2,6-sialyltransferases (Gill et al., 2011; Ju et al., 2011). These steps are depicted in blue and have not been engineered into plants so far. The generation of O-GalNAc residues has been shown (Daskalova et al., 2010; Yang et al., 2012) and the successful expression of the enzymes (GNE, UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase; NANS, N-acetylneuraminic acid phosphate synthase; CMAS, CMP-N-acetylneuraminic acid synthetase; NANP, N-acetylneuraminate-9-phosphate phosphatase, this dephosphorylation step is catalyzed by an endogenous plant enzyme) for CMP-sialic acid synthesis has been demonstrated in A. thaliana and N. benthamiana (Castilho et al., 2008, 2010). In total, the efficient generation of disialylated core 1 structures requires the expression of at least nine non-plant proteins. According to a recent publication the ectopic expression of a UDP-GalNAc transporter is not essential for efficient O-glycosylation initiation in N. benthamiana (Yang et al., 2012). The requirement of the specific chaperone Cosmc for core 1 β1,3-galactosyltransferase folding and activity needs to be tested in plants.

Similar articles

Cited by

References

    1. Aggarwal S. (2010). What’s fueling the biotech engine – 2009–2010. Nat. Biotechnol. 28 1165–1171 - PubMed
    1. Alonso A. P., Piasecki R. J., Wang Y., LaClair R. W., Shachar-Hill Y. (2010). Quantifying the labeling and the levels of plant cell wall precursors using ion chromatography tandem mass spectrometry. Plant Physiol. 153 915–924 - PMC - PubMed
    1. Amano K., Chiba Y., Kasahara Y., Kato Y., Kaneko M. K., Kuno A., Ito H., Kobayashi K., Hirabayashi J., Jigami Y., Narimatsu H. (2008). Engineering of mucin-type human glycoproteins in yeast cells. Proc. Natl. Acad. Sci. U.S.A. 105 3232–3237 - PMC - PubMed
    1. Bakker H., Bardor M., Molthoff J., Gomord V., Elbers I., Stevens L., Jordi W., Lommen A., Faye L., Lerouge P., Bosch D. (2001). Galactose-extended glycans of antibodies produced by transgenic plants. Proc. Natl. Acad. Sci. U.S.A. 98 2899–2904 - PMC - PubMed
    1. Bennett E. P., Mandel U., Clausen H., Gerken T. A., Fritz T. A., Tabak L. A. (2012). Control of mucin-type O-glycosylation: a classification of the polypeptide GalNAc-transferase gene family. Glycobiology 22 736–756 - PMC - PubMed

LinkOut - more resources